Leishmania purine salvage pathway enzyme

The Leishmania purine salvage pathway enzymes are a collection of essential enzymes used by Leishmania species to import, metabolize, and incorporate host-derived purine nucleobases and nucleosides into their nucleotide pools, as the parasite lacks de novo purine synthesis[1][2][3][4]. The key enzymes include hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), xanthine phosphoribosyltransferase (XPRT), adenosine kinase (AK), multiple nucleoside hydrolases, and unique interconversion enzymes such as adenine aminohydrolase (AAH)[1][2][3]. These enzymes are critical for the parasite's survival within the host and are absent or sufficiently different from those in humans to be considered valuable targets in antileishmanial drug design[1][2][4]. Allopurinol, a purine analog, is currently used as a treatment for visceral leishmaniasis in animals, underscoring the clinical potential of this pathway[2]. However, pathway redundancy and enzyme complementarity present therapeutic challenges, and successful intervention may require multi-target strategies[2][4].

Other names

Leishmania purine salvage enzymesLeishmania PSP enzymesLeishmania purine acquisition enzymes

Inhibition of purine salvage enzymes (such as phosphoribosyltransferases and nucleoside hydrolases), leading to nucleotide starvation and parasite death Incorporation of non-natural purine analogs, disrupting nucleic acid synthesis (allopurinol)